Contraindicated (1)bortezomib will improve the level or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or average CYP2C19 inhibitors may raise mavacamten systemic publicity, leading to heart failure as a consequence of systolic dysfunction. To lower the chance of dizziness and lightheadedness, stand up slowly and gradually https://jaspervhsis.dailyblogzz.com/27252621/thalicarpine-an-overview